CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

• 收藏
• 分享

专利权人:

British Columbia Cancer Agency Branch ;British Columbia Cancer Agency Branch

发明人:

SADAR Marianne Dorothy,WANG Jun,MAWJI Nasrin R.,KATO Minoru

申请号：

US201615149298

公开号：

US2017056336(A1)

申请日:

2016.05.09

申请国别(地区):

美国

年份:

2017

代理人:

摘要：

The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound of formula (I), and/or their subgenra, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R8, R9, R11a, R11b, R11c, and R11d are as defined herein, and at least one therapeutically active agents selected from inhibitors of PI3K/AKT/mTOR pathway, active agents associated with the treatment of prostate cancer, and anticancer agents.;

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/